Board of Directors Introduction
 
Company Profile
Our Milestones
Business Overview
Where we operate
Board of Directors Introduction
Corporate Governance
Sales Network
 
Executive Directors Independent Non-Executive Director
Mr. Liu Chengwei
Chairman
Mr. Hu Bo
Deputy Chairman
Dr. Shao Yan
Chief Executive Officer
Dr. Zhang Ji
Executive Director
Ms So Tosi Wan, Winnie
Independent Non-Executive Director
Mr Lo Kai, Lawrence
Independent Non-Executive Director
Dr. Pei Geng
Independent Non-Executive Director

 

Executive Directors


Mr. Liu Chengwei
Chairman
was appointed executive director of the Company in July 2008. Mr Liu is the Chairman of the Company and is a director of Grand Pharm, the principal subsidiary of the Company. Mr. Liu is also a director of Huadong Medicine Company Limited, the shares of which are listed on the main board of the Shenzhen Stock Exchange. Mr. Liu has over 10 years of financial and management experience in the PRC. He is currently the General Manager of the Pharmaceutical Industrial Fund of China Grand Enterprises Incorporation (“China Grand”) and a director of China Grand. Mr. Liu worked for a bachelor degree in International Economics from Peking University and a master’s degree in Business Administration from China Europe International Business School.



Mr. Hu Bo
Deputy Chairman
was appointed executive director of the company in July 2008. Mr. Hu has over 5 years of experience in network project management and property management. He is currently the deputy general manager of a real estate company in the PRC. Mr. Hu holds a bachelor degree in Applied Science & Engineering, Electrical Engineering from University of Toronto. Mr. Hu is a nephew of Mr. Hu Kaijun, the beneficial owner of Outwit, which is the controlling shareholder of the Company.



Dr. Shao Yan
Chief Executive Officer
was appointed executive director of the Company in October 2008. Dr. Shao joined the Company in March 2008 and is the Chief Executive Officer of the Company. Dr. Shao is responsible for overseeing the entire operations and general management of the Company. He has over 20 years of experience in corporate management and venture capital investment. He hold a master’s degree in Business Administration from Guanghua School of Management of Peking University and a doctor degree (PhD) in Management from School of Politics and international Studies of Beijing Normal University.



Dr. Niu Zhanqi
Executive Director
Dr. Niu Zhanqi, aged 49, holds a bachelor’s degree in science from Nankai University and a doctoral degree (PhD) in pharmaceutics from Shenyang Pharmaceutical University. Dr. Niuhas more than 10 years’ experience in pharmaceutical research and development. He is currently an executive president of the Pharmaceutical Management Headquarters of ChinaGrand Enterprises Incorporation (“China Grand”), which is a company established in China and is controlled and ultimately and beneficially owned by Mr. Hu Kaijun, a controlling shareholder (as defined in the Rules Governing the Listing of the Securities on The StockExchange of Hong Kong Limited (the “Listing Rules”)) of the Company. He has also been a director of Huadong Medicine Company Limited (“Huadong Medicine”), which is listed on the Shenzhen Stock Exchange (stock code: 000963), since June 2016. Huadong Medicine is owned as to approximately 41.77 % by China Grand as at the date of this announcement, and is therefore a connected person (as defined in the Listing Rules) of the Company.



Independent Non-Executive Director


Ms So Tosi Wan, Winnie
Independent Non-Executive Director
was appointed independent non-executive director of the Company in March 2005. Ms So is a fellow member of the Association of Chartered Certified Accountants and a practicing member of the Hong Kong Institute of Certified Public Accountants. She is a partner of an accounting firm.



Mr Lo Kai, Lawrence
Independent Non-Executive Director
was appointed independent non-executive director of the Company in June 2008. Mr Lo has over 20 years of experience in wealth and asset management business. Currently, he is the CEO, Asia of UBP Asset Management Ltd. Prior to that, he was the CEO of BSI-Generali Asia (“BSI”) and was responsible for wealth management and asset management activities in Asia. Prior to BSI, he was the CEO of BNP Paribas Asset Management Asia, Head of Asset Management and Private Banking Asia for Banque Paribas from 1993 to 2000. Mr Lo holds a Master of Science degree in Economics at London School of Economics and Political Science.



Dr. Pei Geng
Independent Non-Executive Director
is currently working in Multiway Trading Intl., USA and its Beijing branch, with TDR company in the USA. Dr. Pei has specialized his work in the areas of neurosurgery and neuroscience for over 20 years. Dr. Pei holds a bachelor degree in Medicine and clinically became a medical doctor after graduation from Beijing Capital University of Medicine, China. Dr. Pei also holds a licentiate degree in Medical Sciences from Uppsala University of Medicine, Sweden and a PhD degree in neuroscience from University of Würzburg, Germany.

 
© 2018 China Grand Pharmaceutical and Healthcare Holdings Limited. All Rights Reserved. Disclaimer Powered by EQS TodayIR